NDRC Official Admits 80% Of China’s Imported Drugs More Pricey Than H.K., Korea, Taiwan
This article was originally published in PharmAsia News
A senior pricing official of China’s National Development and Reform Commission (NDRC) admitted that of China’s over 300 stated-regulated imported drugs, 80% are more expensive than South Korea, Hong Kong and Taiwan, but 70% are cheaper than Europe, the U.S. and Japan.
You may also be interested in...
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
Vifor CEO Stefan Schulze tells Scrip that an expanded deal with Korsuva developer Cara Therapeutics means the US biotech will not have to invest in a commercial organization as the Swiss firm will mobilize its well-established sales force to launch the treatment for dialysis patients with CKD-associated pruritus.